On the other hand, although statistical significance was not reached, the use of GLP-1RAs showed a trend towards a reduced risk of nine respiratory diseases (pneumonia, pulmonary fibrosis, dyspnea, acute respiratory failure, pleural effusion, COPD, sleep apnea syndrome, and pulmonary embolism)
o headache, dizziness, and tiredness.
In the postpartum context, understanding your genetic predispositions in these peptide pathways may help provide context for why you experience certain metabolic patterns or appetite changes, supporting a more personalized conversation with your provider about whether GLP-1 medication is appropriate for your recovery and long-term health goals
A more serious concern with long term GLP-1RA usage relates to the potential increased risk for PDAC due to promoting cellular proliferation